SPRB Stock Forecast 2025-2026
Distance to SPRB Price Targets
SPRB Price Momentum
10 Quality Stocks Worth Considering Now
Researching Spruce Biosciences (SPRB) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on SPRB and similar high-potential opportunities.
Latest SPRB Stock Price Targets & Analyst Predictions
Based on our analysis of 9 Wall Street analysts, SPRB has a neutral consensus with a median price target of $1.50 (ranging from $1.00 to $3.00). Currently trading at $0.34, the median forecast implies a 347.8% upside. This outlook is supported by 0 Buy, 5 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Jonathan Wolleben at JMP Securities, projecting a 795.5% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
SPRB Analyst Ratings
SPRB Price Target Range
Latest SPRB Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for SPRB.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 16, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Neutral | Reiterates | $0.00 |
| Dec 12, 2024 | Guggenheim | Evan Wang | Neutral | Reiterates | $0.00 |
| Dec 11, 2024 | Oppenheimer | Hartaj Singh | Perform | Downgrade | $0.00 |
| Dec 11, 2024 | RBC Capital | Gregory Renza | Sector Perform | Reiterates | $1.50 |
| Dec 11, 2024 | JMP Securities | Jonathan Wolleben | Market Perform | Downgrade | $3.00 |
| Nov 12, 2024 | RBC Capital | Gregory Renza | Sector Perform | Reiterates | $2.00 |
| Aug 19, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Neutral | Reiterates | $0.00 |
| Aug 13, 2024 | RBC Capital | Gregory Renza | Sector Perform | Reiterates | $2.00 |
| Jun 13, 2024 | Oppenheimer | Hartaj Singh | Outperform | Maintains | $3.00 |
| Jun 5, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Neutral | Reiterates | $0.00 |
| May 14, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Neutral | Reiterates | $0.00 |
| Mar 14, 2024 | RBC Capital | Gregory Renza | Sector Perform | Downgrade | $2.00 |
| Mar 14, 2024 | Ladenburg Thalmann | Aydin Huseynov | Neutral | Downgrade | $0.00 |
| Mar 14, 2024 | JMP Securities | Jonathan Wolleben | Market Outperform | Maintains | $3.00 |
| Mar 14, 2024 | Leerink Partners | Joseph Schwartz | Market Perform | Downgrade | $2.00 |
| Mar 14, 2024 | Guggenheim | Evan Wang | Neutral | Downgrade | $0.00 |
| Mar 14, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Neutral | Downgrade | $0.00 |
| Mar 5, 2024 | RBC Capital | Gregory Renza | Outperform | Reiterates | $9.00 |
| Feb 26, 2024 | RBC Capital | Gregory Renza | Outperform | Maintains | $9.00 |
| Feb 21, 2024 | Guggenheim | Evan Wang | Buy | Initiates | $10.00 |
Spruce Biosciences Inc. (SPRB) Competitors
The following stocks are similar to Spruce Biosciences based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Spruce Biosciences Inc. (SPRB) Financial Data
Spruce Biosciences Inc. has a market capitalization of $13.84M with a P/E ratio of -0.3x. The company generates $7.10M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is -80.4% quarter-over-quarter, while maintaining an operating margin of -1,562.8% and return on equity of -57.6%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Spruce Biosciences Inc. (SPRB) Business Model
About Spruce Biosciences Inc.
Develops therapies for endocrine disorders.
Spruce Biosciences generates revenue through the development of innovative treatments for rare hormone-related diseases. The company collaborates with medical professionals and research institutions to expedite the delivery of its therapies, thereby addressing significant unmet medical needs in the healthcare sector.
The company's focus on rare diseases positions it uniquely in the biotechnology and pharmaceuticals industry, potentially offering significant growth opportunities as it pioneers novel therapeutics for conditions that currently have limited treatment options.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
22
CEO
Dr. Javier Szwarcberg M.D., M.P.H.
Country
United States
IPO Year
2020
Website
sprucebio.comSpruce Biosciences Inc. (SPRB) Latest News & Analysis
Penny Stock Spruce Biosciences Winds Down Tildacerfont Studies For Rare Genetic Disorder
3 months agoSpruce Biosciences reported topline results from its CAHmelia-204 and CAHptain-205 studies on tildacerfont for adult and pediatric CAH patients.
Spruce Biosciences’ study results on tildacerfont could impact its stock performance and future revenue potential, influencing investor sentiment and market valuation.
Spruce Biosciences (SPRB) has been upgraded to a Zacks Rank #2 (Buy), indicating increasing optimism about its earnings prospects.
The upgrade to Zacks Rank #2 signals increased confidence in Spruce Biosciences’ earnings potential, suggesting potential stock price appreciation and attracting investor interest.
Spruce Biosciences will halt investments in its genetic disorder drug following the failure to meet primary objectives in a mid-stage study.
Spruce Biosciences' failure in a key drug trial signals potential financial loss and diminished future prospects, impacting investor confidence and stock performance.
Spruce Biosciences (Nasdaq: SPRB) announced topline results from its CAHmelia-204 and CAHptain-205 studies of tildacerfont for treating congenital adrenal hyperplasia (CAH).
Positive topline results from Spruce Biosciences' studies could lead to advancements in treatment for CAH, potentially increasing the company's market value and attracting investor interest.
Spruce Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
4 months agoSpruce Biosciences reported Q3 2024 financial results, highlighting progress in developing therapies for endocrine and neurological disorders and plans to release efficacy and safety data soon.
Spruce Biosciences' financial results and updates on CAHmeli's efficacy and safety data could influence stock performance, signaling potential growth or risks in their pipeline.
Spruce Biosciences (SPRB) reported a quarterly loss of $0.21 per share, beating the Zacks Consensus Estimate of $0.27 and improving from a loss of $0.30 per share a year earlier.
Spruce Biosciences' smaller-than-expected loss indicates improving financial performance, which may boost investor confidence and attract interest in the stock.
Frequently Asked Questions About SPRB Stock
What is Spruce Biosciences Inc.'s (SPRB) stock forecast for 2025?
Based on our analysis of 9 Wall Street analysts, Spruce Biosciences Inc. (SPRB) has a median price target of $1.50. The highest price target is $3.00 and the lowest is $1.00.
Is SPRB stock a good investment in 2025?
According to current analyst ratings, SPRB has 0 Buy ratings, 5 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.34. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for SPRB stock?
Wall Street analysts predict SPRB stock could reach $1.50 in the next 12 months. This represents a 347.8% increase from the current price of $0.34. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Spruce Biosciences Inc.'s business model?
Spruce Biosciences generates revenue through the development of innovative treatments for rare hormone-related diseases. The company collaborates with medical professionals and research institutions to expedite the delivery of its therapies, thereby addressing significant unmet medical needs in the healthcare sector.
What is the highest forecasted price for SPRB Spruce Biosciences Inc.?
The highest price target for SPRB is $3.00 from Jonathan Wolleben at JMP Securities, which represents a 795.5% increase from the current price of $0.34.
What is the lowest forecasted price for SPRB Spruce Biosciences Inc.?
The lowest price target for SPRB is $1.00 from at , which represents a 198.5% increase from the current price of $0.34.
What is the overall SPRB consensus from analysts for Spruce Biosciences Inc.?
The overall analyst consensus for SPRB is neutral. Out of 9 Wall Street analysts, 0 rate it as Buy, 5 as Hold, and 0 as Sell, with a median price target of $1.50.
How accurate are SPRB stock price projections?
Stock price projections, including those for Spruce Biosciences Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
